



Lab No.

: SG2/26-08-2024/SR9565422

**Patient Name** : RUMPA DAS : 28 Y 7 M 13 D Age

Gender :F

: Sevoke Road, Siliguri 734001 Lab Add.

Ref Dr. : Dr.MEDICAL OFFICER

**Collection Date** : 26/Aug/2024 09:00AM Report Date : 26/Aug/2024 03:38PM

#### DEPARTMENT OF BIOCHEMISTRY

DEPARTMENT OF BIOCHEMISTRY  Test Name Result Bio Ref. Interval Unit					
Test Name	Result	BIO Ref. Interval	Unit		
CREATININE, BLOOD , GEL SERUM (Method: ALKALINE PICRATE )	0.48	0.50 - 1.10	mg/dl		
URIC ACID,BLOOD (Method:URICASE ,COLORICMETRIC )	3.4	2.6 - 6.0	mg/dl		
CHLORIDE,BLOOD (Method:ISE INDIRECT)	106	98 - 107	mEq/L		
LIPID PROFILE, GEL SERUM					
CHOLESTEROL-TOTAL (Method:CHOLESTEROL OXIDASE, ESTERASE,PEROXIDASE)	131	Desirable: < 200 mg/dL Borderline high: 200-239 High: > or =240 mg/dL	mg/dl		
TRIGLYCERIDES (Method:ENZYMATIC, END POINT)	<u>45</u>	NORMAL < 150 BORDERLINE HIGH 150-199 HIGH 200-499 VERY HIGH 500			
HDL CHOLESTEROL (Method:DIRECT MEASURE-PEG)	60	NO RISK : >60 mg/dL, MODERATE RISK : 40-60 mg/dL, HIGH RISK : <4 mg/dL			
LDL CHOLESTEROL DIRECT (Method:DIRECT MEASURE )	64	OPTIMAL: <100 mg/dL, Near optimal/ above optimal: 100-129 mg/dL, Borderline high: 130-159 mg/dL, High: 160-189 mg/dL, Very high: >=190 mg/dL	mg/dl		
VLDL (Method:Calculated)	7	< 40 mg/dl	mg/dL		
CHOL HDL Ratio (Method:Calculated)	<u>2.2</u>	LOW RISK 3.3-4.4 AVERAGE RISK 4.47-7.1 MODERATE RISK 7.1-11.0 HIGH RISK >11.0			
SODIUM,BLOOD (Method:ISE INDIRECT)	<u>134</u>	136 - 145	mEq/L		
UREA,BLOOD (Method:UREASE-COLORIMETRIC)	23	12.8-42.8	mg/dl		
POTASSIUM,BLOOD (Method:ISE INDIRECT)	4.13	3.5 - 5.1	mEq/L		
PHOSPHORUS-INORGANIC,BLOOD (Method:UV PHOSPHOMOLYBDATE)	4.1	2.5-4.5 mg/dl	mg/dl		
*TOTAL PROTEIN [BLOOD] ALB:GLO R	ATIO , .				
TOTAL PROTEIN (Method:BIURET METHOD)	7.1	6.6 - 8.7	g/dL		
ALBUMIN (Method:BCP)	3.9	3.4 -5.0 g/dl	g/dl		
GLOBULIN (Method:Calculated)	3.2	1.8-3.2	g/dl		
AG Ratio (Method:Calculated)	1.22	1.0 - 2.5			

\*GLYCATED HAEMOGLOBIN (HBA1C), EDTA WHOLE BLOOD

GLYCATED HEMOGLOBIN (HBA1C) 4.5 \*\*\*FOR BIOLOGICAL REFERENCE %

INTERVAL DETAILS, PLEASE

Page 1 of 11





MC-2176

**Lab No.** : SG2/26-08-2024/SR9565422

: F

Patient Name : RUMPA DAS

Age : 28 Y 7 M 13 D

Gender

Collection Date

Report Date : 26/Aug/2024 03:38PM

: Sevoke Road, Siliguri 734001

: Dr.MEDICAL OFFICER

: 26/Aug/2024 09:00AM



#### DEPARTMENT OF BIOCHEMISTRY

Lab Add.

Ref Dr.

Test Name	Result	Bio Ref. Interval	Unit	
		REFER TO THE BELOW MENTIONED REMARKS/NOT WITH ADDITIONAL CLINICAL INFORMATION ***		
HbA1c (IFCC) (Method:HPLC)	26		mmol/mol	

NOTE: Patients HPLC shows > 30 % Hb fraction in variant window, Which suggests some form of Heamoglobinopathy. HPLC typing study is suggested to find the type of Haemoglobinopathy.

#### Clinical Information and Laboratory clinical interpretation on Biological Reference Interval:

Analyzer used : Bio-Rad D 10 Method : HPLC Cation Exchange

#### Recommendations for glycemic targets

- Ø Patients should use self-monitoring of blood glucose (SMBG) and HbA1c levels to assess glycemic control.
- Ø The timing and frequency of SMBG should be tailored based on patients' individual treatment, needs, and goals.
- Ø Patients should undergo HbA1c testing at least twice a year if they are meeting treatment goals and have stable glycemic control.
- Ø If a patient changes treatment plans or does not meet his or her glycemic goals, HbA1c testing should be done quarterly.
- Ø For most adults who are not pregnant, HbA1c levels should be <7% to help reduce microvascular complications and macrovascular disease . Action suggested >8% as it indicates poor control.
- Ø Some patients may benefit from HbA1c goals that are stringent.

Result alterations in the estimation has been established in many circumstances, such as after acute/ chronic blood loss, for example, after surgery, blood transfusions, hemolytic anemia, or high erythrocyte turnover; vitamin B12/ folate deficiency, presence of chronic renal or liver disease; after administration of high-dose vitamin E / C; or erythropoietin treatment.

Reference: Glycated hemoglobin monitoring BMJ 2006; 333;586-8

#### References:

- 1. Chamberlain JJ, Rhinehart AS, Shaefer CF, et al. Diagnosis and management of diabetes: synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes. Ann Intern Med. Published online 1 March 2016. doi:10.7326/M15-3016.
- 2. Mosca A, Goodall I, Hoshino T, Jeppsson JO, John WG, Little RR, Miedema K, Myers GL, Reinauer H, Sacks DB, Weykamp CW. International Federation of Clinical Chemistry and Laboratory Medicine, IFCC Scientific Division. Global standardization of glycated hemoglobin measurement: the position of the IFCC Working Group. Clin Chem Lab Med. 2007;45(8):1077-1080.

#### PDF Attached

*THYROID PANEL (T3, T4, TSH) , GEL SERUM				
T3-TOTAL (TRI IODOTHYRONINE) (Method:CLIA)	0.98	0.60 - 1.81 ng/ml	ng/ml	
T4-TOTAL (THYROXINE) (Method:CLIA)	6.2	4.5 - 10.9	microgram/dl	
TSH (THYROID STIMULATING HORMONE) (Method:CLIA)	3.41	0.35-5.5	μIU/mL	

BIOLOGICAL REFERENCE INTERVAL: [ONLY FOR PREGNANT MOTHERS]

Trimester specific TSH LEVELS during pregnancy:
FIRST TRIMESTER : 0.10 2.50 µ IU/mL
SECOND TRIMESTER : 0.20 3.00 µ IU/mL

**Lab No.** : SG2/26-08-2024/SR9565422 Page 2 of 11





MC-2

 Patient Name
 : RUMPA DAS
 Ref Dr.
 : Dr.MEDICAL OFFICER

 Age
 : 28 Y 7 M 13 D
 Collection Date
 : 26/Aug/2024 09:00AM

 Gender
 : F
 Report Date
 : 26/Aug/2024 03:38PM



#### DEPARTMENT OF BIOCHEMISTRY

Test Name Result Bio Ref. Interval Unit	it
---	----

THIRD TRIMESTER :0.30 3.00 µ IU/mL

#### References:

Lab No.

- 1.Indian Thyroid Society guidelines for management of thyroid dysfunction during pregnancy. Clinical Practice Guidelines, New Delhi: Elsevier; 2012.
- 2. Stagnaro-Green A, Abalovich M, Alexander E, Azizi F, Mestman J, Negro R, et al. Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and Postpartum. Thyroid 2011;21:1081-25.
- 3. Dave A, Maru L, Tripathi M. Importance of Universal screening for thyroid disorders in first trimester of pregnancy. Indian J Endocr Metab [serial online] 2014 [cited 2014 Sep 25]; 18: 735-8. Available from: http://www.ijem.in/text.asp?2014/18/5/735/139221.

CALCIUM,BLOOD (Method:OCPC)	8.8	8.6-10.0 mg/dl	mg/L	
GLUCOSE,PP (Method:Hexokinase Method)	92	75-140	mg/dl	
GLUCOSE,FASTING (Method:Hexokinase Method)	84	70 - 100	mg/dl	

\*\*\* End Of Report \*\*\*

Dr. Ankush Chakraborty MBBS, MD (Path), IFCAP Consultant Pathologist Reg. No. 65992 (WBMC)

**Lab No.** : SG2/26-08-2024/SR9565422 Page 3 of 11





MC-2176

**Lab No.** : SG2/26-08-2024/SR9565422

:F

Patient Name : RUMPA DAS

Age : 28 Y 7 M 13 D

Gender

Lab Add.

Report Date

: Sevoke Road, Siliguri 734001

Ref Dr. : Dr.MEDICAL OFFICER
Collection Date : 26/Aug/2024 09:00AM

: 26/Aug/2024 09:00AM : 26/Aug/2024 06:01PM



#### DEPARTMENT OF HAEMATOLOGY

Test Name	Result	Bio Ref. Interval	Unit	

CBC WITH PLATELET (THROMBOCYTE	) COUNT , EDTA WHOLE BLOOD			
HEMOGLOBIN	10.9	12 - 15	g/dL	
(Method:SLS haemoglobin method)				
WBC	5.7	4 - 10	*10^3/µL	
(Method:DC detection method)				
RBC	4.36	3.8 - 4.8	*10^6/µL	
(Method:DC detection method)		4-0 4-044040	******	
PLATELET (THROMBOCYTE) COUNT	286	150 - 450*10^3	*10^3/µL	
(Method:DC detection method/Microscopy)				
DIFFERENTIAL COUNT				
NEUTROPHILS	60	40 - 80 %	%	
(Method:Flowcytometry/Microscopy)				
LYMPHOCYTES	36	20 - 40 %	%	
(Method:Flowcytometry/Microscopy)		0.400/	0.4	
MONOCYTES	02	2 - 10 %	%	
(Method:Flowcytometry/Microscopy)	00	4 60/	0/	
EOSINOPHILS (Method:Flowcytometry/Microscopy)	02	1 - 6 %	%	
BASOPHILS	00	0-0.9%	%	
(Method:Flowcytometry/Microscopy)	00	0-0.976	78	
CBC SUBGROUP				
HEMATOCRIT / PCV	<u>34.4</u>	36 - 46 %	%	
(Method:Calculated)	<del>57.7</del>	30 - 40 70	76	
MCV	78.9	83 - 101 fl	fl	
(Method:Calculated)	100	33 13111		
MCH	<u>25</u>	27 - 32 pg	pg	
(Method:Calculated)	_	1.0	1.5	
MCHC	31.7	31.5-34.5 gm/dl	gm/dl	
(Method:Calculated)		-		
RDW - RED CELL DISTRIBUTION WIDTH	<u>16.3</u>	11.6-14%	%	
(Method:Calculated)				
PDW-PLATELET DISTRIBUTION WIDTH	24.0	8.3 - 25 fL	fL	
(Method:Calculated)	40.0	,, _ a		
MPV-MEAN PLATELET VOLUME	13.0	7.5 - 11.5 fl		
(Method:Calculated)	MICDOCYTIC LIVEOCLUDORUS			
RBC	MICROCYTIC HYPOCHROMIC			
	MILD ANISOPOIKILOCYTOSIS			
WBC	. NODMAL MODDLIOLOGY			
WBC.	NORMAL MORPHOLOGY.			
PLATELET	ADEQUATE ON SMEAR.			

ESR (ERYTHROCYTE SEDIMENTATION RATE), EDTA WHOLE BLOOD

 1stHour
 15
 0.00 - 20.00 mm/hr
 mm/hr

 (Method:Westergren)
 15
 0.00 - 20.00 mm/hr
 mm/hr

BLOOD GROUP ABO+RH [GEL METHOD], EDTA WHOLE BLOOD

ABO

0

(Method:Gel Card)

RH POSITIVE

(Method:Gel Card)

Gel technology Dia Med ID Micro typing system is the latest technology in transfusion Medicine.

It gives more reproducible and standardized test results.

It more repaid, reliable, very sensitive and objective, and hence more consistent and comparable results are obtained.

**Lab No.** : SG2/26-08-2024/SR9565422

Page 4 of 11






Lab No. : SG2/26-08-2024/SR9565422 Lab Add. : Sevoke Road, Siliguri 734001

Ref Dr. : Dr.MEDICAL OFFICER **Patient Name** : RUMPA DAS : 28 Y 7 M 13 D **Collection Date** : 26/Aug/2024 09:00AM Age : F Gender

Report Date : 26/Aug/2024 06:01PM



**Test Name** Result Bio Ref. Interval Unit

Single used cards are individualised for every patient and results can be photographed / scanned and stored for future use. Special instruments that are used only for this technology also reduce risk of any contamination.

Ref:- WHO technical manual on transfusion medicine-Second Edition 2003

(RESULTS ALSO VERIFIED BY : FORWARD AND REVERSE GROUPING (TUBE AND SLIDE METHOD)

**TECHNOLOGY USED: GEL METHOD** 

#### ADVANTAGES:

- Gel card allows simultaneous forward and reverse grouping.
- Card is scanned and record is preserved for future reference.
- Allows identification of Bombay blood group.
- Daily quality controls are run allowing accurate monitoring.

Historical records check not performed.

\*\*\* End Of Report \*\*\*

Dr. Ankush Chakraborty MBBS, MD (Path), IFCAP **Consultant Pathologist** Reg. No. 65992 (WBMC)

Lab No. SG2/26-08-2024/SR9565422



**Lab No.** : SG2/26-08-2024/SR9565422

Patient Name : RUMPA DAS Ref Dr. : Dr.MEDICAL OFFICER

Age : 28 Y 7 M 13 D Collection Date

**Gender** : F Report Date : 26/Aug/2024 10:37AM



#### DEPARTMENT OF X-RAY

Lab Add.

# DEPARTMENT OF RADIOLOGY X-RAY REPORT OF CHEST (PA)

#### **FINDINGS:**

- Cardiac size appears within normal limits. Margin is well visualised and cardiac silhoutte is smoothly outlined. Shape is within normal limit.
- Lung parenchyma shows no focal lesion. No general alteration of radiographic density. Apices are clear. Bronchovascular lung markings are within normal.
- · Lateral costo-phrenic angles are clear.
- Domes of diaphragm are smoothly outlined. Position is within normal limits.

M	<u>P</u>	<u>R</u>	<u>ES</u>	<u> </u>	<u> 10</u>	N	:
No	r	m	al	st	uc	yk	

\*\*\* End Of Report \*\*\*

DR. Ziaul Mustafa MD, Radiodiagnosis

**Lab No.** : SG2/26-08-2024/SR9565422 Page 6 of 11



**STRAW** 

**CLEAR** 

5.0

1.005

**ABSENT** 

**ABSENT** 

**ABSENT** 

**ABSENT** 

**ABSENT** 

**ABSENT** 

**ABSENT** 

**ABSENT** 

1-2

2-3

**ABSENT** 

**ABSENT** 

**ABSENT** 

PRESENT(+)

PRESENT(+)

ABSENT



**Lab No.** : SG2/26-08-2024/SR9565422

: RUMPA DAS

: 28 Y 7 M 13 D

Gender : F

URINE ROUTINE ALL, ALL, URINE
PHYSICAL EXAMINATION

**CHEMICAL EXAMINATION** 

(Method:Dipstick (protein error of pH

(Method:Dipstick (triple indicator method))

(Method:Dipstick (ion concentration method))

(Method:Dipstick(glucose-oxidase-peroxidase

(Method:Dipstick (pseudoperoxidase reaction))

(Method:Dipstick (azo-diazo reaction)/Manual)

(Method:Dipstick (ester hydrolysis reaction))

MICROSCOPIC EXAMINATION

LEUKOCYTES (PUS CELLS)

(Method:Dipstick (diazonium ion reaction)/Manual)

KETONES (ACETOACETIC ACID,

(Method:Dipstick (Legals test)/Manual)

**Patient Name** 

**COLOUR** 

PROTEIN

ndicators)/Manual)
GLUCOSE

nethod)/Manual)

ACETONE)

BLOOD

**BILIRUBIN** 

**NITRITE** 

UROBILINOGEN

(Method:Microscopy)
EPITHELIAL CELLS

(Method:Microscopy)
RED BLOOD CELLS

(Method:Microscopy)

(Method:Microscopy)
CRYSTALS

(Method:Microscopy)

(Method:Microscopy)

(Method:Microscopy)
OTHERS

**BACTERIA** 

YEAST

CAST

(Method:Dipstick (Griess test))

LEUCOCYTE ESTERASE

рΗ

**APPEARANCE** 

SPECIFIC GRAVITY

Age

Lab Add. : Sevoke Road, Siliguri 734001

Ref Dr. : Dr.MEDICAL OFFICER

Collection Date : 26/Aug/2024 10:18AM

: 26/Aug/2024 03:57PM

/hpf

/hpf

/hpf

### DEPARTMENT OF CLINICAL PATHOLOGY

Report Date

4.6 - 8.0

1.005 - 1.030

NOT DETECTED

NOT DETECTED

NOT DETECTED

NOT DETECTED

**NEGATIVE** 

**NEGATIVE** 

**NEGATIVE** 

**NEGATIVE** 

0-5

0-5

0-2

NOT DETECTED

NOT DETECTED

NOT DETECTED

NOT DETECTED

Test Name Result Bio Ref. Interval Unit



#### Note:

- 1. All urine samples are checked for adequacy and suitability before examination.
- 2. Analysis by urine analyzer of dipstick is based on reflectance photometry principle. Abnormal results of chemical examinations are confirmed by manual methods.
- 3. The first voided morning clean-catch midstream urine sample is the specimen of choice for chemical and microscopic analysis.
- 4. Negative nitrite test does not exclude urinary tract infections.
- 5. Trace proteinuria can be seen in many physiological conditions like exercise, pregnancy, prolonged recumbency etc.
- 6. False positive results for glucose, protein, nitrite, urobilinogen, bilirubin can occur due to use of certain drugs, therapeutic dyes, ascorbic acid, cleaning agents used in urine collection container.
- 7. Discrepancy between results of leukocyte esterase and blood obtained by chemical methods with corresponding pus cell and red blood cell count by microscopy can

**Lab No.** : SG2/26-08-2024/SR9565422

Page 7 of 11





**Lab No.** : SG2/26-08-2024/SR9565422

Patient Name : RUMPA DAS

Age : 28 Y 7 M 13 D

Age : 28 Y 7 M 13 D

Gender : F

Lab Add. : Sevoke Road, Siliguri 734001

Ref Dr. : Dr.MEDICAL OFFICER

Collection Date : 26/Aug/2024 10:18AM

Report Date : 26/Aug/2024 03:57PM

#### DEPARTMENT OF CLINICAL PATHOLOGY

Test Name Result Bio Ref. Interval Unit

occur due to cell lysis.

8. Contamination from perineum and vaginal discharge should be avoided during collection, which may falsely elevate epithelial cell count and show presence of bacteria and/or yeast in the urine.

\*\*\* End Of Report \*\*\*

Dr. Ankush Chakraborty MBBS, MD (Path), IFCAP Consultant Pathologist Reg. No. 65992 (WBMC)

**Lab No.** : SG2/26-08-2024/SR9565422 Page 8 of 11

E-mail: info@surakshanet.com | Website: www.surakshanet.com



Lab No. : SG2/26-08-2024/SR9565422

**Patient Name** 

: RUMPA DAS Ref Dr. : Dr.MEDICAL OFFICER

Lab Add.

Age : 28 Y 7 M 13 D **Collection Date** 

: F Report Date : 26/Aug/2024 12:22PM Gender



#### DEPARTMENT OF CARDIOLOGY

## DEPARTMENT OF CARDIOLOGY **REPORT OF E.C.G.**

**HEART RATE** 80 /min. **RHYTHM** Regular sinus.

P-WAVE Normal

P-RINTERVAL 160 ms,

**QRS CONFIGURATION** NORMAL

**QRS DURATION** 

**QRS VOLTAGE** R/S in V1 0/3 mm.

80

R/S in V6 6/1 mm.

ms

**QRS AXIS** -15°

Q-Waves No significant Q-wave.

**QT TIME** Normal. ST SEGMENT Normal.

T WAVE NORMAL

**ROTATION** Normal.

OTHER FINDINGS Nil.

**IMPRESSION ECG WITHIN NORMAL LIMIT.** 

\*\*\* End Of Report \*\*\*

Dr. ARABINDA SAHA (MD,DM) CONSULTANT CARDIOLOGIST

Page 9 of 11 Lab No. SG2/26-08-2024/SR9565422



Patient Name : RUMPA DAS Ref Dr. : Dr.MEDICAL OFFICER

Age : 28 Y 7 M 13 D Collection Date :

**Gender** : F Report Date : 26/Aug/2024 05:13PM

#### DEPARTMENT OF ULTRASONOGRAPHY

# DEPARTMENT OF ULTRASONOGRAPHY REPORT ON EXAMINATION OF WHOLE ABDOMEN

#### LIVER

Liver is normal in size having normal shape, regular smooth outline and of homogeneous echotexture. No focal parenchymal lesion is evident.Intrahepatic biliary radicles are not dilated. Branches of portal vein are normal

#### **PORTA**

The appearance of porta is normal. Common Bile duct is normal with no intraluminal pathology (Calculi /mass) could be detected at its visualsed part. Portal vein is normal at porta.

#### **GALL BLADDER**

Gallbladder is physiologically distended. Wall thickness appears normal. No intraluminal pathology (Calculi/mass) could be detected. Sonographic Murphys sign is negative.

#### **PANCREAS**

Echogenecity appears within limits, without any focal lesion. Shape, size & position appears normal. No Calcular disease noted. Pancreatic duct is not dilated. No peri-pancreatic collection of fluid noted.

#### SPLEEN

Spleen is normal in size (118 mm). Homogenous and smooth echotexture without any focal lesion. Splenic vein at hilum appears normal. No definite collaterals could be detected.

#### KIDNEYS

Both kidneys are normal in shape, size (Rt. kidney 99 mm. & Lt. kidney 101 mm.) axes & position. Cortical echogenecity appears normal maintaining cortico-medullary differentiation. Margin is regular and cortical thickness is uniform. No calcular disease noted. No hydronephrotic changes detected. Visualised part of upper ureters are not dilated.

#### URINARY BLADDER

Urinary bladder is distended, wall thickness appeared normal. No intraluminal pathology (calculi/mass) could be detected.

#### UTERUS

Uterus is anteverted, normal in size (87 mm. x 46 mm.) Endometrium (collapsed wall) is in midline. Myometrium appears smooth & homogenous without any detectable/sizable focal lesion. Cervix looks normal. Pouch of Douglas is free.

## **OVARIES**

Ovaries are normal in size, shape, position, margin and echotexture.

#### **IMPRESSION:**

Sonographic study of whole abdomen does not reveal any significant abnormality.

#### Kindly note

- > Ultrasound is not the modality of choice to rule out subtle bowel lesion.
- > Please Intimate us for any typing mistakes and send the report for correction within 7 days.

**Lab No.** : SG2/26-08-2024/SR9565422

Page 10 of 11



Lab No. : SG2/26-08-2024/SR9565422

**Patient Name** 

: RUMPA DAS Ref Dr. : Dr.MEDICAL OFFICER

Age : 28 Y 7 M 13 D **Collection Date** 

:F Report Date : 26/Aug/2024 05:13PM Gender



DEPARTMENT OF ULTRASONOGRAPHY

> The science of Radiological diagnosis is based on the interpretation of various shadows produced by both the normal and abnormal tissues and are not always conclusive. Further biochemical and radiological investigation & clinical correlation is required to enable the clinician to reach the final diagnosis.

Lab Add.

#### The report and films are not valid for medico-legal purpose.

Patient Identity not verified.

DR. Ziaul Mustafa MD, Radiodiagnosis


Page 11 of 11 Lab No. SG2/26-08-2024/SR9565422

# **Patient report**

Sample ID: D02135827714

Injection date 26/08/2024 08:04 AM Injection #: 3 D-10 Method: HbA1c Rack position: 3 Rack #: ---

Bio-Rad v: 5.00-2 S/N: #DM23F10804  $0.08_{T}$ 0.07 0.06



Peak table - ID: D02135827714

Peak	R.time	Height	Area	Area %
Unknown	0.14	2235	4214	0.3
A1a	0.23	2460	10886	0.7
A1b	0.30	2841	11394	0.7
F	0.56	1530	11870	0.7
LA1c/CHb-1	0.68	2153	17412	1.1
A1c	0.90	4272	34890	4.5
P3	1.37	20707	85976	5.2
A0	1.45	432181	966602	58.9
Variant-Window	1.58	215946	497001	30.3

1640244 Total Area:

Concentration:	%	mmol/mol
A1c	4.5	26